AVBP
ArriVent BioPharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.90
+1.90%Next report
Analyst consensus
- Next report date
- Nov 16, 2026
- EPS estimate
- -$1.07
- Revenue estimate
- $800.0K
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$1.05
- EPS estimate
- -$0.99
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +3.9%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $44
- PT range
- $40 – $47
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.99 | -$1.05 | Miss -6.35% | — |
| May 11, 2026 | -$0.88 | -$0.96 | Miss -9.09% | — |
| Mar 5, 2026 | -$0.85 | -$0.78 | Beat 7.83% | — |
| Mar 3, 2025 | -$0.78 | -$0.60 | Beat 23.08% | — |
| Nov 14, 2024 | -$0.82 | -$0.61 | Beat 25.61% | — |
| Aug 14, 2024 | -$0.65 | -$0.65 | In line | — |
| Jan 26, 2024 | -$1.10 | -$0.70 | Beat 36.36% | — |
| Jun 30, 2022 | — | -$5.76 | — | — |
| Mar 31, 2022 | — | -$5.76 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 16, 2026